Dr Imanirad on Toxicity Management for Encorafenib Plus Cetu

Dr Imanirad on Toxicity Management for Encorafenib Plus Cetuximab in BRAF-Mutant mCRC

Iman Imanirad, MD, medical oncologist, gastrointestinal oncology, Moffitt Cancer Center, discusses the management of toxicities associated with standard-of-care encorafenib plus cetuximab for patients with previously treated microsatellite stable BRAF V600E metastatic colorectal cancer.

Related Keywords

Iman Imanirad , Moffitt Cancer Center , Cetuximab , Encorafenib , Raf V600e Metastatic Colorectal Cancer , Beacon Crc , Toxicities , Prophylaxis ,

© 2025 Vimarsana